Ignite Creation Date:
2024-05-06 @ 12:44 AM
Last Modification Date:
2024-10-26 @ 10:53 AM
Study NCT ID:
NCT01640444
Status:
COMPLETED
Last Update Posted:
2019-04-11
First Post:
2012-06-13
Brief Title:
Influence of BRAF and PIK3K Status on the Efficacy of 5-FluorouracilLeucovorinOxaliplatin FOLFIRI Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and 3 Circulating Tumor Cells CTC
Sponsor:
Spanish Cooperative Group for the Treatment of Digestive Tumours TTD
Organization:
Spanish Cooperative Group for the Treatment of Digestive Tumours TTD
Study Overview
Official Title:
Randomized Phase II Study to Explore the Influence of BRAF and PIK3K Status on the Efficacy of FOLFIRI Plus Bevacizumab or Cetuximab as First Line Therapy of Patients With RAS Wild-type Metastatic Colorectal Carcinoma and 3 Circulating Tumor Cells
Status:
COMPLETED
Status Verified Date:
2018-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VISNU-2
Brief Summary:
The purpose of the study is to explore the influence of BRAF and PIK3K status on the efficacy of FOLFIRI plus Bevacizumab or Cetuximab as first line therapy of patients with RAS wild-type metastatic colorectal carcinoma and 3 circulating tumor cells
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2012-000840-90 | EUDRACT_NUMBER | None | None |